Loss of pituitary hormone function after stereotactic radiosurgery for pituitary adenomas: mechanisms and management Authors: Christina Abi Faraj, Ian E McCutcheon Published: 2026 ABSTRACT AbstractBackgroundStereotactic radiosurgery (SRS) is an essential modality for treating recurrent or residual pituitary adenomas (PAs), offering high rates of tumor control and moderately effective endocrine management in both functioning (FPAs) and non-functioning pituitary adenomas (NFPAs). Endocrine remission is less consistently achieved, and in hypersecretory states such as acromegaly and Cushing's disease, hormone normalization may be delayed by years relative to surgical resection. The impact of pre-treatment hormone suppression on radiosensitivity remains controversial, with evidence suggesting it may further delay endocrine remission.MethodsA review of the literature was conducted to evaluate the rates and predictors of hypopituitarism following SRS for pituitary adenomas, the differential radiosensitivity of pituitary axes, and strategies aimed at reducing radiation induced endocrinopathy.ResultsHypopituitarism remains the most common complication of SRS, occurring in 21–50% of patients, and arises from radiation-induced damage to the hypothalamus, pituitary gland, or stalk. The radiosensitivity of pituitary axes varies across studies; while some series identify the somatotropic axis as most vulnerable followed by the gonadotropic, corticotropic, and thyrotropic axes, larger multicentric cohorts have reported thyrotropin and cortisol deficiencies as more prevalent. Hypopituitarism may develop years after treatment, underscoring the importance of long-term followup. Advances in volumetric and automated segmentation imaging have improved tumor targeting and reduced unintended radiation exposure to adjacent structures, while strategies such as pituitary transposition and optimized dose protocols have shown promise in mitigating radiation-induced endocrinopathies.ConclusionCurrent evidence underscores the importance of individualized treatment planning, careful dose modulation, and advanced imaging techniques to minimize complications while maintaining therapeutic efficacy. Further research is needed to clarify predictors of hypopituitarism, optimize treatment protocols, and explore strategies to enhance patient outcomes following SRS for pituitary adenomas.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11060-026-05591-7.Keywords: Hypopituitarism, Pituitary adenoma, Pituitary neuroendocrine tumor, Stereotactic radiosurgery, Pituitary hormone Introduction Pituitary adenomas (PAs), also known as pituitary neuroendocrine tumors (PitNETs), form 10% of intracranial tumors [1]. They are classified as nonfunctioning pituitary adenomas (NFPAs) or functioning pituitary adenomas (FPAs) based on the secretion of biologically active pituitary hormones. To date, prolactinomas are treated with dopamine agonists (DAs), with resection reserved for those refractory or intolerant to DAs, while the treatment for symptomatic NFPAs and other FPAs includes surgical resection. Goals of treatment include tumor growth control, optic apparatus decompression, and hormonal hypersecretion/dysfunction treatment. Surgical resection is capable of normalizing hormone levels in FPAs in the majority of patients [2–4]. However, patients with persistent or recurrent endocrinopathies achieve endocrinological remission less often following repeat resection [5]. Furthermore, complete surgical resection is not always achievable, especially in the setting of tumor invasion of the cavernous sinus or sellar dura. Progression of a known residual tumor without adjuvant treatment occurs in around 50% of PAs within 10 years after surgery [6]. In recent practice guidelines by the European Society of Endocrinology for aggressive or metastatic PitNETs [7], radiotherapy was recommended to improve tumor control in patients whose tumor continues to grow despite surgery and standard medical treatment. In cases where surgery leaves behind an invasive tumor remnant that shows predictors of aggressive behavior, such as elevated proliferation markers (mitotic count and Ki67/MIB1 index) or concerning genetic alterations (TP53 and SF3B1 in lactotroph tumors refractory to treatment with dopamine agonists, and TP53 and ATRX in corticotroph macroadenomas), adjuvant radiotherapy may be considered, generally administered around three to six months after surgery. For patients whose tumor progresses rapidly even after a prior course of radiotherapy, a second round of RT can be considered. However, this requires careful evaluation of the cumulative radiation dose to the brain, optic chiasm, and nearby cranial nerves to minimize the risk of harm to surrounding structures. Fractionated external beam radiation therapy results in clinical and biochemical remission in patients with FPAs. Nonetheless, it often disrupts hypothalamic-pituitary axis (HPA) function and requires years to correct hormone overproduction. In the last three decades, stereotactic radiosurgery (SRS) has emerged as an alternative to manage recurrent or residual PAs. SRS is primarily used as adjuvant therapy for patients with residual tumor, salvage therapy for those with tumor regrowth, and/or primary treatment for those with high surgical morbidities [8–10]. The goals of SRS are to halt tumor growth, shrink the tumor, and normalize hormonal hypersecretion, all while minimizing hormonal dysfunction from the tumor itself or the SRS and avoiding radiation injury to adjacent structures such as the optic apparatus, brainstem, and temporal lobe. Hypopituitarism is the most common complication of SRS, with an incidence ranging between 21% and 50%, and increasing over time [10–17]. Hypopituitarism is defined as biochemical deficiency of one or more HPA hormones. It arises from damage to the pituitary gland, infundibulum, or hypothalamus. It can be primary from intrinsic pituitary dysfunction, secondary to mass effect from PA, or iatrogenic from surgery or radiation therapy, alone or in combination [9, 11, 15]. Other SRS-related complications include optic neuropathy, vascular injury, cranial neuropathy, secondary tumor development, and radiation necrosis of the temporal lobe [9]. Therefore, when considering SRS for the treatment of PA, one must take into account the location of the tumor relative to the optic chiasm, brainstem and temporal lobe, tumor size, extent, and shape, and its hypersecretory status. In this review, we discuss the role of SRS in the treatment of PAs, with primary emphasis on the loss of pituitary hormone function following SRS — its incidence, biological mechanisms, predictors, and strategies for its prevention and management. Endocrinological outcomes Normalization of hypothalamic-pituitary axis function in FPAs SRS has proven to be more effective in controlling tumor growth than achieving complete endocrine remission in FPAs [18]. Importantly, tumor shrinkage does not necessarily correlate with hormonal remission, underscoring the value of surgical debulking before SRS for untreated or large recurrent FPAs [19]. Notably, biochemical remission criteria vary considerably across the studies cited in this section, and this heterogeneity is a recognized limitation of the existing literature that precludes direct cross-study comparison of cure rates [18]. In most studies, remission was defined as normalization of hormone levels without the need for suppressive medications. Readers are referred to Supplementary Table 1, which provides the remission definition used in each cited study alongside other key study parameters, for a more granular appraisal of individual series. Several factors influence the likelihood of endocrine remission following SRS (Table 1). Pollock and colleagues identified the absence of hormone-suppressive medications at the time of radiosurgery and a higher maximum radiation dose (> 40 Gy) as significant predictors of remission [20]. Rates and predictors of endocrine remission in FPAs are discussed below. Table 1Factors affecting post SRS endocrine remissionAbsence of hormone-suppressive medications at the time of radiosurgeryHigher maximum radiation dose (> 40 Gy)Acromegaly: lower IGF-I levels (< 2.25 times the upper limit of normal), lower initial GH and IGF-I levels off somatostatin analogues and prior to SRS, absence of cavernous sinus invasion, male genderPRL: smaller tumor volume (< 3 mL), lower prolactin levels (< 200 ng/mL), margin dose greater than 30 GyCushing’s disease: smaller tumor volume, cessation of cortisol-lowering medications around the time of SRS Factors affecting post SRS endocrine remission Acromegaly In a meta-analysis of 28 studies involving 1,335 patients with acromegaly, Mathieu et al. found that tumor control rates varied between 94% and 100%, with endocrine remission rates ranging from 0% to 82% [18]. The random effects estimate for crude remission was 44%. Pollock et al. studied 46 consecutive patients with GH-secreting adenomas and found actuarial biochemical remission rates of 11% at two years and 60% at five years post-SRS [21]. Factors positively associated with remission included lower IGF-I levels (less than 2.25 times the upper limit of normal) and the absence of pituitary suppressive medications at the time of radiosurgery [21–23]. Castinetti et al. showed that SRS is similarly effective whether used as a primary treatment or as an adjunct to surgery [22]. Additional predictors of remission include the absence of cavernous sinus invasion [24], male gender [24], and a higher margin dose [25]. The delay in endocrine remission seems to be longest in acromegaly. Cushing’s disease Gamma Knife radiosurgery is effective in treating recurrent or residual Cushing’s disease, as the typically smaller tumor volumes allow for a highly focused radiation dose while minimizing exposure to nearby structures. A meta-analysis by Mathieu et al. reviewed 13 studies and 416 patients with Cushing’s disease; they reported tumor control rates ranging from 83% to 100% and crude endocrine remission rates from 6% to 81% [18]. The meta-analysis found a random effects estimate of 48% for endocrine remission in Cushing’s disease. In Sheehan et al.‘s study, remission rates were 34%, 54%, 72%, and 78% at one, two, three, and five years post-SRS, respectively [26]. However, 15% of patients experienced an initial remission followed by disease recurrence, with a median time to recurrence of 38 months. There was no significant difference in treatment parameters between those who had a recurrence and those who remained in remission. Predictors of endocrine remission are smaller tumor volume, which allows for a more focused radiation dose, and absence of cortisol-lowering medications at the time of SRS [26, 27]. In Cushing’s disease, the causative adenoma is most often a microadenoma that may be radiologically occult, particularly in patients with a history of prior surgical resection [26]. When biochemical evidence of hypercortisolism is present but no discrete lesion is identifiable on MRI, irradiation of the entire sellar contents has been employed as an alternative targeting strategy. This approach yields endocrine remission rates comparable to those achieved when a discrete target is available, but it carries a significantly higher risk of post-SRS hypopituitarism [26]. Prolactinoma Mathieu et al.’s systematic review included 13 studies involving 538 patients with prolactinomas [18]. Tumor control rates ranged from 86% to 100%, while remission rates varied from 6% to 81%. The random effects meta-analysis estimated crude remission for prolactinomas at 28%. Key predictors of remission included smaller tumor volume (< 3 mL) [28], lower prolactin levels (< 200 ng/mL) [28], and a margin dose greater than 30 Gy [29]. SRS vs. surgical resection Surgical resection remains the gold standard for achieving rapid endocrine remission, with cure rates ranging from 63% to 95% for microadenomas and 47% to 77% for macroadenomas [2–4]. In contrast, remission following SRS typically takes 14 to 16 months [20, 26], with remission in Cushing’s disease often occurring within two to hree years. The effectiveness of surgery diminishes in larger tumors, those showing cavernous sinus invasion, and those with recurrent or persistent hormone hypersecretion, in whom SRS becomes a promising alternative, achieving endocrine cure rates of 50% to 60% [20]. SRS vs. fractionated radiotherapy While no randomized clinical trials have directly compared SRS with fractionated radiotherapy, SRS has shown higher rates of biochemical and endocrinologic remission. Landolt et al. found that GH and IGF-I levels normalized significantly faster after SRS than after fractionated RT (median time: 1.4 years vs. 7.1 years) [19]. The association between fractionated RT and hypopituitarism is discussed in a later section of this review. Does hormone suppression confer radio-resistance? Medications that suppress pituitary hormones are thought to act as radioprotective agents, which may explain why patients with FPAs who receive hormone-suppressive treatments often experience delayed or reduced endocrinologic remission after SRS [26, 30, 31]. As a result, current practice recommends discontinuing hormone-suppressive medications one to four months before SRS, with most guidelines suggesting a cessation period of four to 12 weeks, particularly for patients with stable endocrine status [18]. While there is a need for randomized trials to confirm definitively whether hormone suppression contributes to radio-resistance, temporarily stopping these medications helps establish baseline hormone levels before treatment. However, the impact of these drugs on tumor size post-radiosurgery and their influence on the risk of post-SRS hypopituitarism remain uncertain. No data exist to show whether hormone-suppressive medications taken before or after SRS affect the maintenance of pituitary hormone function long term. Radiation-induced hypopituitarism following SRS Compared to conventional fractionated radiotherapy, which carries risks including endocrinopathies, secondary tumors, internal carotid artery stenosis, and cognitive dysfunction, SRS offers greater precision, reducing radiation exposure to surrounding healthy brain (and other) tissue and lowering the risk of long-term damage [32]. Still, hypopituitarism is a recognized complication following SRS for PAs, affecting a subset of patients due to damage to the HPA. This condition arises from the close proximity of the normal pituitary gland and stalk to the adenoma, leading to unavoidable radiation exposure to these structures. Contributing factors include the tumor’s mass effect and prior surgical manipulation, which increase the risk of injury to the surrounding normal tissues. In most studies, new endocrine deficits after SRS are generally defined by dysfunction in at least one hormone axis, marked by subnormal hormone levels or the need for hormone replacement therapy. Incidence The incidence of hypopituitarism post-SRS varies considerably across studies, ranging from 0 to 36% [8, 15, 19, 25, 33–36]. In patients treated for Nelson’s syndrome specifically, hypopituitarism rates after SRS have ranged from 22% to 40%, with onset occurring between two and nine years post-treatment [37, 38]. The varying rates of hypopituitarism observed are probably linked to differences in patient characteristics, such as previous surgeries or radiation treatments, the prescribed radiation dose, the treatment volume, the duration of follow-up, and the thoroughness of endocrine evaluations. The paucity of a large patient population and long-term follow-up (> 10 years) has hindered rigorous statistical analyses of the long-term risks of hypopituitarism. Reports describing patients followed for less than five years (most series include patients with a follow-up as short as six months) surely underestimates the prevalence of SRS-induced hypopituitarism [16]. Cordeiro and colleagues analyzed 1023 patients with PAs (NFPA[n = 410]; Cushing’s disease [n = 262]; and acromegaly [n = 251]) [11]. With a median follow-up of 51 months, they encountered a rate of 24.2% (248 patients) of new hypopituitarism in PAs. This most often consisted of single hormone deficiency (n = 150), with multiple hormone deficiencies (n = 98) less frequently seen. True panhypopituitarism, including the development of diabetes insipidus, was rare (n = 7). Patients with acromegaly had the highest rate of hypopituitarism (38.7%), followed closely by NFPAs (34.7%), and finally those with Cushing’s disease had the lowest rate (26.6%). A systematic review of outcomes and toxicities of SRS for NFPAs in 2671 patients yielded a random effects estimate of 21.0% for post-SRS hypopituitarism [39]. Another similar systematic review for secretory pituitary adenomas showed post-SRS hypopituitarism random effects estimates of 17% for acromegaly, 21% for Cushing’s disease, and 12% for prolactinomas [18]. In contrast, Dumot et al. explored the rates of new pituitary deficiency by hormone subtype in a larger multicentric sample of 869 patients and found significantly lower rates of hypopituitarism after SRS for NFPAs, with rates of 6.5%, 9.9%, and 15.3% at three, five, and 10 years, respectively [17]. Finally, posterior pituitary deficits, particularly diabetes insipidus (DI) due to vasopressin (antidiuretic hormone, ADH) deficiency, are quite rare after SRS for PAs [11]. Most of the literature focuses on anterior pituitary hormone deficiencies, as these are far more common after SRS due to the anatomical vulnerability of the anterior lobe of the pituitary gland to radiation. The posterior pituitary, responsible for secreting ADH and oxytocin, is typically less affected by SRS because of its more posterior location and because these hormones are produced exclusively by the hypothalamus, not the neurohypophysis. It simply stores and releases them after they are transported down the pituitary stalk from their site of synthesis in the hypothalamus. However, in rare cases SRS can lead to posterior pituitary dysfunction, and to the development of DI, but these occurrences are considered exceptional. Most studies have reported no significant incidence of new-onset diabetes insipidus after SRS for PAs. The role of radiation-induced damage to the stalk or to the hypothalamus in causing diabetes insipidus remains obscure. Pathophysiology and delayed onset Hypopituitarism may take years to develop, with reports of dysfunction occurring up to 12 to 22 years post-SRS [34]. The delayed nature of this complication is in contrast to the timing of other adverse effects, such as cranial nerve deficits, which tend to occur more immediately [20]. Aging can also cause hypopituitarism, as hormone levels tend to be age-dependent, especially when patients are followed for long durations [9]. Hypopituitarism following SRS is multifactorial and occurs through several converging biological mechanisms. At the cellular level, ionizing radiation causes direct DNA double-strand breaks in pituitary and hypothalamic cells, triggering apoptosis and impairing the regenerative capacity of hormone-secreting populations. Radiation-induced vascular injury compounds this direct cytotoxicity: damage to the microvasculature of the hypothalamic-pituitary portal system causes endothelial injury, progressive microvascular occlusion, ischemia, and fibrosis within the gland and stalk, accounting in part for the characteristically delayed and cumulative nature of post-radiation endocrinopathy. A third mechanism involves chronic neuroinflammation mediated by proinflammatory cytokines including TNF-α and IL-1β, which may perpetuate tissue dysfunction long after radiation exposure has ended [40]. Central to understanding these mechanisms is the question of whether injury occurs predominantly at the level of the pituitary itself or upstream at the hypothalamus, a distinction that remains debated and is likely dose-dependent. While several authors have suggested that hypothalamic radiation poses a risk of new onset of hypopituitarism [41, 42], others found that hypothalamic doses during SRS are low enough that the hypothalamus is unlikely to be a major driver of pituitary insufficiency after SRS [11, 12, 36, 43–46]. At higher radiation doses, such as those used for nasopharyngeal carcinoma and skull-base tumors, hypothalamic dysfunction is well-recognized [40] and manifests in characteristic ways: early or accelerated puberty following pituitary irradiation supports a hypothalamic contribution [47], and late hyperprolactinemia — reflecting selective damage to the dopaminergic tuberoinfundibular neurons that normally exert tonic inhibitory control over prolactin secretion — has been attributed to delayed hypothalamic radiation injury [41]. Degerblad et al. further argued that GH deficiency following SRS in patients with Cushing’s disease was hypothalamic in origin and recommended limiting doses delivered to that structure accordingly [41]. When hypothalamic injury does occur, neuronal rather than vascular damage appears to be the predominant mechanism, supported by Chieng and colleagues’ observation that hypothalamic blood flow remains intact in patients who develop hypopituitarism after conventional radiotherapy for nasopharyngeal carcinoma [48]. Additionally, radiosensitivity appears to vary among hypothalamic nuclei [41, 49, 50]: the predilection of the somatotropic axis to fail earliest and at the lowest doses likely reflects the heightened vulnerability of the hypothalamic neurons governing GH release, while the pattern of hyperprolactinemia seen after high-dose conventional radiotherapy reflects selective injury to the dopaminergic tuberoinfundibular system. In the SRS context, however, the hypothalamic contribution is substantially attenuated by the precision of dose delivery. Pomeraniec et al. found that contemporary multi-isocentric dose planning resulted in median hypothalamic doses of only 1.4 Gy, and these doses were not predictive of new or worsening hypopituitarism [12]. Similarly, Feigl and colleagues did not find a significant difference between radiation doses to the hypothalamus in patients with versus those without new endocrine dysfunction after SRS [36]. However, the mean hypothalamic doses in their cohort were 1.3 Gy (hypopituitarism group) vs. 0.8 Gy (no hypopituitarism group), both being very low. Therefore, the lack of significant hypothalamic dose effect on hypopituitarism is not necessarily because the hypothalamus does not play a role; it may simply be because the doses delivered to it are too low across the board to produce a detectable signal either way [12, 36, 44–46]. In support of this interpretation, studies of SRS for acromegaly and prolactinomas in which median eminence doses were higher — approximately 5.5 Gy — did find hypothalamic dose to be a meaningful predictor of endocrine dysfunction [19]. The pathophysiology of delayed endocrine dysfunction after SRS is not well understood. Hypopituitarism may take years to develop, with reports of dysfunction occurring up to 12 to 22 years post-SRS [34]. The delayed nature of this complication is in contrast to the timing of other adverse effects, such as cranial nerve deficits, which tend to occur more immediately [20]. Aging can also cause hypopituitarism, as hormone levels tend to be age-dependent, especially when patients are followed for long durations [9]. In addition, the radiosensitivity of the pituitary axes varies. Vladyka et al. found that the most vulnerable hormone axis is the somatotropic axis, followed by the gonadotropic, corticotropic, and the least vulnerable thyrotropic axes [35]. They hypothesized that the vulnerability of the somatotropic axis could be utilized as a measure of hypopituitarism and radiation damage following SRS. Oh et al. also found that somatotroph impairment is the most common encountered post-SRS hormone axis deficit [14]. In contrast, Dumot et al., whose cohort of 869 patients with NFPA is described above in the Incidence section, found that the 10-year cumulative probability of new pituitary deficiency was 8% for cortisol and thyroid hormones, higher than their gonadotroph (3.5%) and growth hormone (4.7%) counterparts [17]. Cordeiro et al., with a sample size of 1023 patients with NFPA, Cushing’s disease, and acromegaly, found that the most common new hormone deficiency was thyrotropin, followed by gonadotropin, cortisol, and (lowest of all) vasopressin [11]. The five-year risk for subsequent hypoadrenalism, hypogonadism, and hypothyroidism reported by Sicignano et al. was around 10% [51]. These differences in new hormonal deficit rates could be attributed to differences in sample size, multicenter nature of these studies, underreporting of new hormonal deficits, follow-up duration (shorter follow-up favoring detection of the earliest-onset deficits such as GH deficiency, while longer follow-up reveals the accumulating burden of TSH and ACTH deficiency), the radiation doses delivered to individual glandular structures across cohorts, and a potential lack of systematic testing and replacement of GH and gonadotroph hormones, rather than a true differences in radiosensitivity. The prolactin axis warrants particular attention in the context of radiation-induced pituitary injury, as it follows a characteristic biphasic trajectory that is distinct from other hormone axes. Early after irradiation, disruption of hypothalamic dopaminergic input leads to transient hyperprolactinemia, reported in up to 20–50% of patients receiving doses above 40 Gy via external beam RT, and attributable to reduced inhibitory dopamine tone rather than direct lactotroph stimulation [40, 45, 46, 52–54]. However, with extended follow-up, prolactin levels subsequently decline, sometimes falling below the normal range, reflecting progressive, time-dependent radiation injury to the lactotroph cells themselves [40, 52, 55]. This prolactin peak may occur anywhere from one to 16 years after treatment, after which a slow decline ensues [54]. While this pattern has been characterized most extensively in the fractionated RT literature, its relevance to SRS is emerging: prolactin deficiency has been reported six to 20 years after radiation exposure, with onset significantly delayed compared to other anterior pituitary hormone deficits [55, 56]. Notably, this late decline has not been documented following surgery alone, implicating radiation as its primary driver. In long-term survivors of childhood leukemia treated with cranial RT at doses of 18–30 Gy, prolactin insufficiency was documented up to 20 years post-diagnosis, with continued decline observed at five- and eight-year follow-up intervals, and with clinical consequences including failure to lactate in the majority of women who became pregnant during follow-up [55, 57]. Predictors of hypopituitarism Multiple factors predict post-SRS hypopituitarism (Table 2). First, higher radiation doses to the hypothalamus, pituitary stalk, and pituitary gland increase the risk of hormone deficits [10–12, 17, 35, 58]. We discuss reported radiation doses that increase the risk of endocrinopathy in later sections of this review. A history of prior radiation therapy is also predictive of new or worsening endocrinopathy after SRS [10]. Table 2Factors affecting the risk of hypopituitarism post-SRSIncreased riskDecreased riskDose-dependent: higher radiation doses to the hypothalamus, pituitary stalk, and pituitary glandDistance between the center of the pituitary gland and center of the SRS target > 15 mmCavernous sinus invasion†Residual tumors confined to the cavernous sinus†Suprasellar tumor extensionCut-off dose of 5.5 Gy to the stalkTumor volume > 4 cm3Mean doses of 15 Gy to the gonadotropic and thyrotropic axes and 18 Gy to the adrenocorticotropic axisPrior craniotomyReducing the mean dose to the identifiable gland to below 11 GyPrior cranial irradiation50% or higher isodose linePoorly delineated tumorPituitary transposition technique for residual tumors in the cavernous sinusMaximum point dose > 8 to 10 Gy to the stalkPituitary stalk-to-gland dose ratio of at least 0.8Lower isodose lines (below 50%)Other considerations with unclear impact on post-SRS hypopituitarism: pretreatment pituitary gland function, timing of prior treatments, and the rigorousness and length of endocrine follow-up†Cavernous sinus involvement has been associated with both increased and decreased risk of post-SRS hypopituitarism depending on the clinical context. Residual tumor confined to the cavernous sinus after surgical debulking may confer lower risk due to its distance from the pituitary stalk, whereas invasive tumors extending into the cavernous sinus, which are typically larger and require higher doses, are associated with higher stalk dose and greater hypopituitarism risk. The net effect is thus mediated by tumor size, degree of resection, and radiation geometry rather than cavernous sinus location alone Factors affecting the risk of hypopituitarism post-SRS Other considerations with unclear impact on post-SRS hypopituitarism: pretreatment pituitary gland function, timing of prior treatments, and the rigorousness and length of endocrine follow-up †Cavernous sinus involvement has been associated with both increased and decreased risk of post-SRS hypopituitarism depending on the clinical context. Residual tumor confined to the cavernous sinus after surgical debulking may confer lower risk due to its distance from the pituitary stalk, whereas invasive tumors extending into the cavernous sinus, which are typically larger and require higher doses, are associated with higher stalk dose and greater hypopituitarism risk. The net effect is thus mediated by tumor size, degree of resection, and radiation geometry rather than cavernous sinus location alone Second, because maximum point dose to the pituitary stalk is a significant predictor of subsequent pituitary hormone dysfunction [12, 44, 58], Kotecha et al. reasoned that residual tumors confined to the cavernous sinus may confer a lower risk of hypopituitarism as that structure is farther from the pituitary stalk [39]. This contrasts with Cohen-Inbar’s findings that cavernous sinus invasion by the tumor yields a higher risk of hypopituitarism [16]. These apparently contradictory findings between Kotecha et al. and Cohen-Inbar et al. regarding cavernous sinus involvement warrant reconciliation. In Kotecha et al.‘s analysis, the cavernous sinus tumor represented a well-lateralized residual target — anatomically remote from the pituitary stalk — such that the radiation isocenter could be placed at sufficient distance from the stalk and normal gland to limit collateral dose to those structures [39]. Cohen-Inbar et al., by contrast, reasoned that a tumor invading the cavernous sinus generally has larger volumes that require greater radiation doses, and dose delivery to a target in the cavernous sinus inevitably leads to radiosurgical beams passing through the adjacent normal gland and the stalk and hypothalamus above [16]. Therefore, it is not the cavernous sinus location itself that increases hypopituitarism risk, but rather the higher radiation dose required and the inability to avoid irradiating the stalk and residual normal pituitary when treating a large invasive tumor. Tumors that actively invaded the cavernous sinus, which are typically larger, have greater suprasellar extent, and require radiation fields that necessarily traverse the normal gland and stalk en route to the lateral target, increasing the risk of hypopituitarism. Suprasellar PA extension also increases the risk of developing loss of pituitary function after SRS [42]. A greater distance between the center of the pituitary gland and center of the SRS target, specifically > 15 mm, is shown to reduce the risk of hypopituitarism [13]. Therefore, in the setting of cavernous sinus invasion or extrasellar extension, it is crucial to delineate the stalk and residual normal pituitary gland to ensure they do not fall in a high-dose radiation area. Adenoma volume is also predictive of post-SRS hypopituitarism. Pollock et al. reported that patients with an adenoma volume > 4 cm3 were more likely to develop new anterior pituitary hormone deficiency [8]. This is not a surprise, as a larger treatment volume generally exposes the normal gland to higher doses of radiation. The inevitable distortion of the normal pituitary gland imposed by large sellar tumors may itself weaken the secretory capacity of the gland, and/or impair the rhythmicity of hormone release. Other predictors of hypopituitarism after SRS include pretreatment pituitary gland function, the modality and timing of prior treatments, prior craniotomy, prior radiotherapy, and the rigorousness and length of endocrine follow-up [14, 33, 58–60]. Prior craniotomy may have caused partial compromise of pituitary function and blood supply prior to radiosurgery. On the other hand, one can argue that surgery holds the advantage of debulking macroadenomas that may be occupying the entire sella, compressing and hindering a proper view of the pituitary gland. SRS after surgery would then target the residual tumor rather than the more clearly demarcated gland. This is opposite to utilizing SRS as up-front treatment for macroadenomas, in which case the entire sella would be irradiated and the pituitary gland that is compressed by the tumor would automatically be irradiated as well. Leenstra et al. found a poorly delineated tumor to be associated with post-SRS endocrine deficits [15]. In those with clearly delineated tumors, increasing radiation dose was a predictor of subsequent new or worsening hypopituitarism. Target delineation is crucial in FPAs, as they are most frequently caused by microadenomas that are often difficult to detect on imaging, especially in cases where prior surgical resection has altered the anatomy of the sella [61]. In these patients, irradiation of the entire sella, including the tumor and normal neurovascular structures, has been utilized. As discussed in the Endocrinological Outcomes section, whole-sella irradiation carries a significantly higher risk of hypopituitarism compared to targeted radiation, despite comparable remission rates [26, 62]. The degree of PRL deficiency may also serve as a clinically useful surrogate marker of the overall burden of radiation-induced pituitary injury [55]. Evidence from hypothalamic-pituitary disease cohorts shows a stepwise increase in the rate of PRL deficiency with each additional hormone axis lost — from none in patients with intact pituitary function to 38% in those with four concurrent hormone deficits — suggesting that severe hypoprolactinemia reflects extensive glandular damage rather than isolated lactotroph injury [55, 63]. In patients with severe hypopituitarism, PRL deficiency has been found to be independently associated with reduced IGF-I status, further linking it to the somatotropic axis [64]. Clinicians should therefore consider including basal PRL measurement as part of the routine endocrine surveillance panel in patients who have undergone SRS, particularly those with multiple pre-existing or evolving hormone deficiencies, in whom low PRL may signal a higher degree of cumulative pituitary damage. Hypopituitarism in patients with pre-existing pituitary hormone dysfunction A major challenge in assessing post-SRS hypopituitarism is that many patients already have pituitary deficiencies due to compression of gland by tumor, or to previous surgery or radiation, or some combination thereof. Current research has not thoroughly investigated whether SRS exacerbates pre-existing hypopituitarism or how it impacts endocrine deficits in patients with prior hormone deficiencies. Key questions remain unanswered, such as whether patients with pre-existing hormonal dysfunction are at greater risk of additional pituitary damage after SRS, or whether they require higher doses of hormone replacement following treatment. Most studies do not differentiate between new-onset and worsened hypopituitarism, making it difficult to parse out the specific effects of SRS on endocrine function. Theoretically, patients with partial hypopituitarism before SRS may be at higher risk for worsening hormonal deficiencies, as the remaining functional pituitary tissue could be more susceptible to radiation-induced damage. Prior microvascular injury may also be aggravated by radiation, potentially leading to more gradual and prolonged hypopituitarism. The data on this topic are mixed. Some studies found that pre-existing hypopituitarism at the time of SRS did not predict new-onset hypopituitarism [11, 15]. In contrast, others observed a higher incidence of hypopituitarism in patients with normal pre-SRS hormone levels (41.7%) compared to those with pre-existing deficits (10.3%) [14, 58]. However, in Pollock and Young’s series of 11 patients with Nelson’s syndrome who had undergone bilateral adrenalectomy to control persistent cortisol hypersecretion in Cushing’s disease, complications (including injury to cavernous sinus contents, hypopituitarism, and temporal lobe radionecrosis) occurred only in patients who had been previously exposed to fractionated radiation therapy [60]. These findings suggest that patients with pre-existing partial endocrine deficits are not as likely to develop new hormonal deficiencies after SRS, potentially because the previous damage, whether it originated from neuronal or vascular injury or from direct compression, exerts a masking effect in which additional radiation-induced injury remains subclinical because the hormonal axes were already compromised. When the functional reserve of the pituitary is already be diminished, further deficits are less apparent clinically. Alternatively, this observed effect could reflect the inherent variability in individual susceptibility of the various hormone axes to radiation damage; in that scenario, those most vulnerable to radiation damage would have already been affected. Further research with larger cohorts and extended follow-up periods is needed to understand better the relationship between pre-existing hypopituitarism and post-SRS outcomes. Dose-response and dose-toxicity relationships Appropriate SRS doses reduce the risk of radiation-induced endocrinopathy Figure 1 shows an algorithm for the management of PA with SRS. Radiation-induced hypopituitarism is strongly dose-dependent, with higher radiation exposure to the hypothalamus, pituitary stalk, and pituitary gland increasing the risk of hormone deficiencies. The selection of radiation dose depends on whether the PA is functioning or non-functioning. As FPAs typically require higher doses to achieve endocrine remission, they present a different risk-benefit profile compared to NFPAs, for which the goal is primarily tumor control and growth suppression. In FPAs, achieving hormone suppression is challenging, especially when the tumor is small and radiographically indistinguishable from adjacent normal structures. The mechanism of endocrine remission in FPAs entails disruption of protein biosynthesis, while disruption of the cell cycle and halting of subsequent cellular division is the main mechanism for growth suppression in NFPAs [10]. Algorithm for the management of pituitary adenomas with SRS The biologically effective dose, rather than the radiation dose alone, is a better predictor of endocrine remission in acromegaly patients treated with SRS [23]. Longer treatment times allow for more DNA repair, reducing the biological effectiveness of the radiation dose. Vladyka et al. also argued that the mean dose to the pituitary, rather than the maximum dose, is the key determinant of new hypopituitarism; the mean dose affects the entire gland, whereas the maximal dose is localized. The maximal dose, does, however, play a critical role in promoting injury to the pituitary stalk [35]. Several studies have investigated the minimal effective dose to minimize damage to the pituitary gland and stalk. Feigl et al. demonstrated that higher point doses to these structures predict endocrine insufficiency [36]. They found a direct association between total radiation dose and pituitary hormone insufficiency in 43.5% of 108 patients treated with SRS over a median follow-up of 6.6 years [36]. In their study, patients with post-SRS pituitary dysfunction had significantly higher mean doses to the pituitary stalk (6.5 Gy vs. 4.1 Gy) and the gland (12.4 Gy vs. 9.5 Gy) than did patients who maintained normal hormone function. They recommended a cut-off dose of 5.5 Gy to the stalk to mitigate the risk of post-SRS hypopituitarism. Similarly, Vladyka et al., whose radiosensitivity findings were described above, further characterized specific dose thresholds: the risk of hypopituitarism increased at mean doses of 15 Gy to the gonadotropic and thyrotropic axes and 18 Gy to the adrenocorticotropic axis, with the rate of dysfunction reaching 60–85% at doses between 17 and 20 Gy [35]. Patients who had undergone prior surgery were particularly vulnerable to hypopituitarism. This differential sensitivity among the various hormonal axes explains why post-irradiation panhypopituitarism occurs less often than loss of function in a single hormonal axis. Other studies have provided safe radiation dose protocols. Oh et al. suggested mean and maximal dose cut-offs for the stalk (7.56 Gy and 12.3 Gy, respectively) and the gland (maximal dose of 13.9 Gy, minimal dose of 5.25 Gy) [14]. Sicignano et al. proposed that doses of 15.7 Gy to the gland and 7.3 Gy to the stalk are associated with an increased risk of endocrinopathy [51]. The lower tolerance of the stalk compared to the gland may be due to the higher density of blood vessels in the stalk [36]. Pomeraniec et al. confirmed that higher doses to the pituitary stalk are linked to increased risk of endocrinopathy after SRS [44], with a maximum point dose > 8 Gy being associated with hypopituitarism [58]. Dumot et al. additionally reported that doses exceeding 10 Gy to the stalk are a significant predictor of hormone deficiency [17]. In contrast, Marek et al. found a 73% risk of hypopituitarism in patients treated with mean pituitary doses greater than 15 Gy, compared to only a 2% risk in those receiving doses below 15 Gy [65]. The dose to the distal pituitary stalk was also a significant predictor of hypopituitarism in their series. They recommended a maximum dose of 17 Gy to the distal pituitary stalk to avoid dysfunction. Graffeo et al. further suggested that reducing the mean dose to the identifiable gland to below 11 Gy could help lower the incidence of new hormonal deficits after SRS for PAs [66]. Some studies have also explored dose ratios along the HPA, finding that a pituitary stalk-to-gland dose ratio of at least 0.8 significantly increases the risk of hypopituitarism [12]. Another factor to consider is that the suprasellar extension of a pituitary adenoma has been shown to be a potent predictor of hypopituitarism, the mechanism of which could be related to higher doses to the pituitary stalk [39, 42]. Thus, it is important to create a favorable distance between the suprasellar region and the residual tumor if complete resection is not feasible; this strategy would theoretically reduce the risk of delayed hypopituitarism [42, 67]. In the same Cordeiro et al. cohort described above, lower isodose lines were associated with a higher incidence of new hypopituitarism [11]. Specifically, for every 10% reduction in the isodose line, the risk of hypopituitarism increased by 27%. Lower isodose lines at the margin increase the maximum dose delivered to the tumor but also elevate the dose to nearby structures such as the pituitary gland, stalk, and hypothalamus. By prescribing a 50% or higher isodose line, clinicians can optimize the dose gradient beyond the tumor edge, reducing radiation exposure to adjacent structures while maintaining an effective therapeutic dose. A higher isodose line enables the tumor to receive more homogeneous high-dose radiation with an increased mean dose. With an increased mean dose, the treatment dose can be optimized by reducing the maximum dose delivered to the center of the target while maintaining the same dose at the margin. This allows neighboring structures to receive less radiation, reducing the risk of hypopituitarism. Ultimately, Cohen-Inbar et al. concluded that no true “safe dose” exists below which a patient is free from the risk of developing hypopituitarism [16]. However, the radiosurgical dose to the target should not be compromised in an attempt to avoid hypopituitarism, as delayed hormone deficiencies can be managed through supplementation [42]. Endocrine remission and tumor growth control are essential in patients with functioning PAs, and achieving these outcomes may necessitate higher margin doses. Appropriate SRS doses for durable tumor growth control A range of 12 to 20 Gy has been used for the treatment of NFPAs, with doses of 12 to 16 Gy showing durable tumor control [39]. Dumot et al. found that a margin dose of 14 Gy was associated with effective tumor control [17]. A larger multi-institutional study by Sheehan et al. on 512 patients with NFPAs reported that a median dose of 16 Gy resulted in tumor control rates of 95% at five years and 85% at ten years [10]. Cohen-Inbar reported that a cut-off margin dose of < 17 Gy was significantly associated with a higher rate of NFPA progression [68]. For ACTH-secreting tumors, doses typically range from 18 to 25 Gy [42]. Zhang et al. reported improved tumor control, as well as resolution of hypertension and hyperglycemia, in 68 patients with acromegaly treated with margin doses greater than 30 Gy [25]. In prolactinomas, a margin dose of ≥ 30 Gy has also been linked to effective treatment of hyperprolactinemia [29]. In 2022, the International Stereotactic Radiosurgery Society provided updated recommendations for the use of SRS in the management of FPAs, following a systematic review and meta-analysis of available literature [18]. While previous guidelines suggested a dose of 14–16 Gy for single-fraction SRS, the studies reviewed lacked long-term follow-up data beyond ten years [39]. In their more recent work, due to the heterogeneity of the studies reviewed, no specific recommendation was made regarding the optimal prescription dose [18]. Fractionated RT and hypo-fractionated stereotactic RT vs. single-fraction SRS As noted in the Endocrinological Outcomes section, SRS and fractionated RT have been compared primarily for remission speed; here we address their comparative impact on hypopituitarism. The growth hormone axis is particularly vulnerable to fractionated RT, with deficiency rates reaching 50–100% within three to five years of cranial irradiation at doses of 30–50 Gy. In contrast, TSH and ACTH deficiencies occur in 3–6% of cases, and gonadotropin deficiencies are dose dependent. Generally, the rates of gonadotropin, ACTH, and TSH deficiencies substantially increase after intensive irradiation for non-pituitary tumors or conventional fractionated radiation for pituitary tumors, with the cumulative incidence reaching 30–60% after 10 years. Hyperprolactinemia, usually subclinical, is seen predominantly in young women after intensive irradiation (> 60 Gy). SRS is associated with a lower likelihood of early anterior-pituitary hormone deficiency in pituitary adenomas compared to fractionated radiotherapy. However, the long-term cumulative incidence of hypopituitarism between the two modalities may be similar [34]. Studies investigating hypo-fractionated stereotactic radiotherapy for PAs have generally not provided adequate data from which we can draw solid conclusions on long-term outcomes. Hypofractionation schedules include 21 Gy in three fractions, 20 Gy in four fractions, and 25 Gy in five fractions. Data from these studies show high tumor control rates with low associated toxicity, but long-term data are lacking [69]. In contrast, Kotecha et al. found no association between tumor control and doses as a function of tumor volume and suggested that dose and fractionation are important for the prevention of toxicity to the optic pathways rather than for tumor control [39]. Therefore, fractionation is used for tumors near the optic pathways or for tumors that have been previously irradiated. Further studies are needed to optimize fractionated approaches and patient selection. Optimal SRS dose that balances tumor control, endocrine remission, and hypopituitarism risk The available evidence does not support a single optimal radiation dose that universally balances tumor control, endocrine remission, and hypopituitarism risk — nor can it, given that these three objectives are inherently in tension and their dose requirements vary by adenoma subtype. For NFPAs, where endocrine remission is not a competing goal, the evidence most consistently supports a margin dose of 12–16 Gy as providing durable tumor control at an acceptable hypopituitarism risk. For FPAs, higher margin doses are typically required to achieve endocrine remission, and the resulting increase in radiation exposure to the normal gland and stalk makes some degree of hypopituitarism risk unavoidable. In this context, dose to specific structures is a more actionable target than margin dose alone: constraining the maximum point dose to the pituitary stalk below 8 Gy, mean dose to the gland below 11–15 Gy, and prescribing an isodose line of 50% or higher to optimize the dose gradient beyond the tumor edge represent the most consistently supported dosimetric strategies for minimizing hypopituitarism risk without compromising treatment efficacy. Where tumor proximity to the optic apparatus or prior irradiation limits single-fraction dosing, hypofractionation offers a means of achieving an equivalent biological dose with a more favorable toxicity profile. Ultimately, the evidence supports an individualized, structure-specific dosimetric approach rather than a universal dose prescription, with treatment objectives and acceptable risk thresholds tailored to adenoma subtype, tumor geometry, and prior treatment history. Technical strategies to reduce risk Pituitary transposition: is it helpful? Pituitary transposition (hypophysopexy) has been proposed as a technique to increase the distance between the pituitary gland and the target region for radiation, and aims to protect the gland from radiation-induced damage [67]. The procedure involves a standard endonasal transsphenoidal approach, wherein a maximal resection of the tumor in the sella is performed while leaving some residual tumor in the cavernous sinus. Autologous fat and/or fascia lata, harvested from the patient’s abdomen or thigh, are then used for the transposition. During the surgery, the normal pituitary gland is carefully dissected away from the residual tumor and repositioned laterally, away from the involved cavernous sinus. A margin of healthy tissue is also removed from the tumor interface to ensure that no part of the lesion remains attached to the gland before transposition. Fat is then placed between the gland and the residual tumor to maintain the displacement (Fig. 2). Following surgery, patients typically undergo SRS or fractionated stereotactic radiotherapy within three weeks to prevent resorption of the interposed fat graft before radiation therapy begins. Pituitary transposition approach. After tumor resection, the pituitary gland (P) is pushed laterally away from the residual tumor (T) in the left cavernous sinus. An autologous fat graft (F) is then placed between the pituitary gland and the cavernous sinus and secured with a layer of DuraSeal® (D). The residual tumor can then be treated with SRS. Adapted with modification from Taussky et al. [67] Taussky et al. evaluated the effectiveness of this technique in a study involving 34 patients with NFPAs [67]. Of these, two patients developed postoperative endocrine deficits before radiosurgery (one transient), but none experienced new-onset hypopituitarism during a median follow-up period of four years (range, 1–8 years) after undergoing SRS or fractionated stereotactic radiotherapy. Thus, placing a fat graft between the residual tumor in the cavernous sinus and the normal pituitary gland in patients slated for SRS may be a promising approach for reducing radiation-induced damage to healthy structures. However, a randomized trial is necessary to evaluate fully the effectiveness of this technique, particularly since tumors in the cavernous sinus may pose a lower risk of post-SRS hypopituitarism compared to tumors in other regions of the sella, although as discussed in the Predictors section, the relationship between cavernous sinus involvement and hypopituitarism risk is ambiguous [39]. Optimal timing of SRS after surgery: early vs. delayed (on-progression) Prior radiosurgical studies have explored the optimal timing for SRS following surgical resection of NFPAs, suggesting that performing SRS within six months of surgery may result in better tumor control compared to delayed SRS [58, 70]. Early SRS is usually reserved for cases in which the tumor was surgically challenging, or those in which adenoma remnants were located near the optic nerve. In other cases, maximal tumor resection is performed, and SRS is only considered if tumor progression occurs during long-term follow-up. In a large multi-center cohort study of 111 matched patients, early SRS (within six months) reduced the risk of radiological progression of subtotally resected NFPAs compared to delayed SRS [70]. Interestingly, this study found no significant difference in the risk of new endocrinopathies based on the timing of SRS. In contrast, another retrospective review of 51 patients did not find statistically significant differences in tumor control or the incidence of post-SRS hormonal deficiencies between early and late SRS [14]. However, the small number of cases in the early SRS group (only five) limited the statistical power of the study, making it difficult to draw definitive conclusions about the optimal timing of SRS after transsphenoidal surgery. Another important factor to consider when determining the timing of SRS for residual tumors is the distance between the residual tumor and the pituitary stalk. The same study showed that the immediate postoperative distance between the stalk and the residual tumor was 14.02 ± 7.32 mm, but this distance had decreased to 4.01 ± 3.46 mm at the time of SRS. This reduction in distance was not due to tumor regrowth but rather to the natural restoration of the stalk toward the midline. This phenomenon raises the need for further research to determine whether early or late SRS is more appropriate, considering this recovery of the stalk’s position. Mantziaris et al. further investigated tumor control and hypopituitarism rates in a matched cohort study of 260 patients with residual NFPA, comparing adjuvant (ADJ) SRS with SRS performed at the time of tumor progression (PRG) [58]. Their findings showed no statistically significant difference in radiological tumor control or pituitary function between the two groups. The five-year tumor control rates were 94.8% for the ADJ group and 98.6% for the PRG group. Additionally, the five- and 10-year risks of new-onset hypopituitarism were 13.7% and 23.5% in the ADJ group, compared to 13.3% and 15.5% in the PRG group. Despite the lack of significant difference in hypopituitarism rates, the PRG group had a longer median time to new pituitary dysfunction than the ADJ group (58.9 months vs. 29.7 months), suggesting a potential benefit of delayed SRS in extending the time to onset of hormonal deficiencies. Imaging techniques for precise target delineation Defining the optimal target volume for a PA is a balance between high tumor control and low toxicity. Careful delineation of all the organs at risk of radiation damage surrounding the target volume is crucial (Fig. 3). Pre-contrast and post-contrast MRI sequences are used for precise target delineation. An equation most often used to estimate PA volume, i.e., volume = abc/2, is a simplified ellipsoid volume formula in which “a” corresponds to length, “b” is width, and “c” is height of the lesion). Some have also used the formula for volume of a sphere (4 π (mean radius)3 /3). PAs, especially after resection, are often irregularly shaped and manual segmentation is not only time-consuming but can fall short of accurate tumor delineation. Poor visualization of the pituitary gland on dose planning correlates with a higher risk of new hypopituitarism after SRS [15]. Thus, three-dimensional volumetric assessment of PAs is more accurate than 2D or 1D measurements [71]. Contrast-enhanced 3D T1-weighted sequences with 1 mm thin slices are extremely useful for accurate target delineation. Automated volumetric segmentation by way of machine learning models may provide a faster and more accurate avenue for tumor delineation. Currently, manual slice-by-slice volumetric calculation of the overall volume is more accurate than other semiautomatic methods for 3D volume assessment [72]. In future, automated segmentation of PA is likely to prove helpful in delineating such targets with accuracy and precision. Anatomical targeting considerations for SRS. Coronal, axial, and sagittal views of target delineation for a pituitary adenoma. Gross total volume/Planning target volume (GTV/PTV) and organs at risk are outlined: GTV/PTV (red), optic chiasm (yellow), pituitary gland (orange), pituitary stalk (pink), brainstem (green), right and left optic nerves (dark blue), right and left hippocampus (light blue), hypothalamus (purple) Special situations SRS for the prevention and treatment of Nelson’s syndrome Nelson’s syndrome, which can occur after bilateral adrenalectomy (BLA) in patients with Cushing’s disease, is characterized by the rapid growth of ACTH-secreting pituitary tumors. Traditional management options include surgical resection and medical therapy, but SRS is also being used to treat this condition. Patients at risk of Nelson syndrome include those with a preexisting incompletely treated PA. Nonetheless, some patients with Cushing’s disease show no tumor on MRI of the sella, and it is not clear whether those who later develop PA harbored tiny post-operative foci of tumor below the limits of detectability, or whether the decline in circulating glucocorticoids after adrenalectomy encourages initiation of new tumors from normal anterior pituitary cells [73]. This distinction is crucial because SRS post-BLA could prevent the development of Nelson’s syndrome. Bunevicius et al. investigated whether SRS on residual PAs before BLA could reduce this risk [74]. Their findings showed that 22% of patients (9 out of 43) developed Nelson’s syndrome at a median of 24 months post-BLA. They found that SRS before BLA significantly decreased the risk of developing Nelson’s syndrome, while elevated ACTH levels within six months after BLA were linked to an increased risk. SRS has also been used after BLA for treating active Nelson’s syndrome, achieving tumor control rates of up to 90%. However, SRS appears to be less effective for achieving endocrine remission in Nelson’s syndrome compared to Cushing’s disease, with incidence of such remission ranging from 10% to 35% [37, 38, 60]. This is supported by a multicenter study by Cordeiro et al., which reported 51 patients treated with single-fraction SRS (median margin dose of 25 Gy). In this study, 62.7% of patients experienced a decrease in ACTH levels post-SRS, but only 29.4% achieved remission without medical management at the last follow-up, despite a tumor control rate of 92.2% [38]. ACTH-secreting pituitary tumors that appear after adrenalectomy are likely biologically different from those seen in typical Cushing’s disease. These tumors tend to invade parasellar structures more aggressively and grow at a faster rate, making them harder to treat surgically and less responsive to radiotherapy [73]. The primary goal of treating Nelson’s syndrome is to control adenoma growth and prevent damage to surrounding visual and neural structures [38]. The incidence of radiation-induced hypopituitarism following SRS for Nelson’s syndrome is discussed in the Incidence subsection above. It is not clear whether the timing of SRS before vs. after adrenalectomy in patients being treated for Nelson’s syndrome, has any effect on the incidence of subsequent impairment of one or more anterior pituitary hormonal axes. Whole sella vs. targeted radiation Persistent hormone hypersecretion following surgical resection may result from microscopic invasive disease, multifocal adenoma remnants along the edge of the resection cavity, or radiographically occult tumor [75]. In such cases, where no clear target is identifiable on MRI, irradiation of the entire sella may be necessary to achieve remission, with endocrine outcomes comparable to those obtained by targeting a defined lesion [26, 62, 75] (Fig. 4). Radiation dose distribution treating the entire sella in residual pituitary adenoma. Post-contrast T1-weighted MRI in axial (left), coronal (upper right), and sagittal (lower right) planes demonstrating the radiosurgical target volume in a patient with Cushing's disease who has had two transsphenoidal operations attempting gross total resection of a microadenoma in the right side of the pituitary gland. Because biochemical remission was not achieved, stereotactic radiosurgery targeting the entire sella was undertaken. The yellow contour delineates the target volume encompassed within the 24 Gy isodose line, incorporating the sellar floor, the medial walls of both cavernous sinuses, and the entire pituitary gland. The dosimetry plan was optimized to cover all areas that might contain residual tumor while limiting the dose to the optic apparatus to less than 8 Gy to prevent radiation-induced optic neuropathy Management and suggested follow-up Given the delayed and progressive nature of radiation-induced hypopituitarism after SRS, long-term endocrine surveillance is mandatory. Baseline pituitary function testing should be performed prior to SRS and repeated at six-to-twelve-month intervals thereafter, with particular attention to the somatotropic axis given its early vulnerability, and to all axes in patients with pre-existing partial deficits or those who have undergone combined surgery and SRS. Hormone replacement therapy should be initiated promptly upon biochemical confirmation of deficiency, as untreated hypopituitarism is associated with increased cardiovascular morbidity and reduced quality of life. Surveillance should extend beyond ten years given the documented occurrence of new hormonal deficits at this time point and beyond [34]. Limitations of SRS SRS, while an effective treatment for PAs, has several limitations. One significant drawback is the delay in achieving hormone normalization, with many patients requiring months to years for complete biochemical remission, especially in conditions like acromegaly or Cushing’s disease. Similarly, tumor volume control is not immediate; tumor shrinkage occurs gradually, and in some cases, the tumor may remain stable without substantial reduction in size. In patients in whom a macroadenoma has caused hypopituitarism, SRS cannot shrink tumor sufficiently nor reliably enough to bring back normal function, and inclusion of the gland in the target volume militates against endocrine recovery. Another challenge arises when the tumor is radiologically occult or has indistinct margins, particularly postoperatively when surgically induced fibrosis complicates tumor visualization on MRIs. This increases the risk of targeting errors and can lead to complications such as hypopituitarism due to inadvertent radiation exposure to surrounding normal pituitary tissue. Moreover, the proximity of the target tumor to critical structures like the optic nerves limits the maximal dose of radiation that can be safely administered, posing a challenge in achieving optimal tumor control without risking vision loss. Dose modulation and precise target delineation near vital structures, such as the optic chiasm or cavernous sinus, are also complex and require highly specialized imaging and expertise to minimize collateral damage. Additionally, larger or more invasive tumors may be less responsive to SRS, as the treatment’s effectiveness diminishes with increased tumor volume and invasion into adjacent structures, sometimes necessitating multimodal therapy. Limitations of existing literature Several limitations of the existing literature merit acknowledgment. Most studies are retrospective, with significant heterogeneity in patient selection, radiation protocols, and diagnostic criteria for hypopituitarism, limiting direct comparisons across series. Follow-up durations are frequently insufficient to capture the full cumulative burden of radiation-induced endocrine dysfunction, which can manifest a decade or more after treatment, leading to likely underestimation of true hypopituitarism prevalence. Prolactin deficiency is rarely assessed as an independent endpoint, further contributing to underreporting. Most studies do not differentiate between new-onset and worsened pre-existing hypopituitarism, making it difficult to isolate the specific contribution of SRS to endocrine dysfunction in patients with prior hormonal deficits. The generalizability of reported dose-response relationships to patients with genetically determined pituitary adenomas — including MEN1, AIP mutation-associated familial isolated pituitary adenomas, and Carney complex — remains unknown, as existing series do not stratify outcomes by genetic status and such patients are frequently underrepresented. Finally, the absence of randomized controlled trials comparing SRS with fractionated radiotherapy or observation precludes definitive conclusions about relative hypopituitarism risk across modalities. Prospective registries incorporating standardized endocrine assessment, extended follow-up, and stratification by genetic status are needed to address these gaps. Conclusion SRS has established itself as an effective treatment for recurrent or residual pituitary adenomas, demonstrating high rates of tumor control in both functioning and nonfunctioning PAs. However, hypopituitarism remains the most common complication, with varying radiosensitivity among pituitary cell types—growth hormone-secreting cells being particularly vulnerable. Key predictors of hypopituitarism include higher radiation doses, suprasellar tumor extension, cavernous sinus involvement, larger tumor volume, and prior treatments. Poorly delineated tumors also increase the likelihood of post-SRS endocrine deficits, as the pituitary gland is more likely to receive unintended radiation in such cases. Whole-sella irradiation and fractionated radiation therapy carry a higher risk of hypopituitarism compared to more targeted, single-fraction treatments. Other notable complications following SRS for PAs include radiation-induced optic neuropathy and radionecrosis of the temporal lobe, both of which are dose-dependent. Current guidelines recommend keeping radiation doses to the optic apparatus below 12 Gy to minimize the risk of optic neuropathy, and caution is advised for patients who have previously undergone radiation treatment to the sella. To reduce the risk of optic neuropathy, hypofractionated radiotherapy may be used for PAs in close proximity to the optic apparatus or in previously irradiated tumors. Additionally, achieving endocrine control is the primary goal in treating FPAs. SRS is generally more effective at controlling tumor growth than inducing endocrine remission, and the criteria for endocrine cure vary significantly among studies, complicating direct outcome comparisons. The timeline for tumor control and endocrine remission is longer with SRS compared to surgical resection, requiring patients to tolerate elevated hormone levels for an extended period. Hormone-suppressive medications may act as radioprotective agents, reducing or delaying hormonal normalization. While SRS remains a powerful tool in the management of PAs, further research is needed to optimize treatment protocols, especially in understanding factors that influence remission timelines and reduce post-SRS hypopituitarism and visual dysfunction. Long-term follow-up is crucial to detect delayed-onset hypopituitarism. Additional research is warranted to improve and automate PA detection and segmentation on MRI, particularly in postoperative cases where fibrosis complicates accurate tumor delineation. Lastly, it is essential to investigate more deeply whether SRS exacerbates pituitary dysfunction in patients with pre-existing endocrinopathy. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Adrenocorticotropic hormone Anti–diuretic hormone Adjuvant Dopamine agonist Diabetes insipidus Functioning pituitary adenoma Gross tumor volume Insulin–like growth factor-I Nonfunctioning pituitary adenoma Pituitary adenoma Pituitary neuroendocrine tumor On–progression Planning target volume Stereotactic radiosurgery Author contributions Conception and design: I.E.M.Data collection: C.A.F.Data analysis and interpretation: C.A.F., I.E.M.Manuscript writing: C.A.F., I.E.M.Final approval of manuscript: C.A.F., I.E.M. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.